, Volume 23, Issue 2, pp 185-196

First online:

HIV therapeutic possibilities of gold compounds

  • Pascaline N. FontehAffiliated withDepartment of Biochemistry, University of Pretoria
  • , Frankline K. KeterAffiliated withDepartment of Biochemistry, University of Pretoria
  • , Debra MeyerAffiliated withDepartment of Biochemistry, University of Pretoria Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Highly active antiretroviral therapy (HAART) has resulted in decreased mortality and morbidity from the acquired immune deficiency syndrome caused by the human immunodeficiency virus (HIV). Drug resistance and toxicity of HAART has led to the search for novel inhibitors of HIV infection. Gold-based compounds have shown promising activity against a wide range of clinical conditions and microorganism infections including HIV-1. A typical example is auranofin which resulted in an elevated CD4+ T-cell count in an HIV patient being treated for psoriatic arthritis. In addition, reports exist on gold-based inhibitors of reverse transcriptase (RT), protease (PR) and viral entry of host cells. These and other characteristics of gold-based HIV drugs are reviewed here.


Gold Inhibitors HIV AIDS